OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
July 02, 2020
EMA is facing a dilemma in trying to restore activities back to normal after relocating and the COVID-19 pandemic.
As Brexit talks intensify, bio/pharma companies from both the UK and EU need to consider and aim to prepare for all scenarios.
June 05, 2020
The protocol on Northern Ireland (NI) once Brexit has been completed has received mixed opinions in industry, according to various press releases.
February 27, 2020
ABPI has issued a statement noting that it shares the ambition of the United Kingdom’s government, as set out in its published approach to the negotiations for the future relationship with the European Union (EU).
February 13, 2020
According to executive search firm Odgers Berndtson, its recent poll has highlighted that senior executives in life sciences believe there is a positive future for the United Kingdom’s sector outside the European Union.
February 02, 2020
The UK and Europe are entering a transitional period, which will involve negotiations across the board, including those on the pharma regulatory landscape.
January 02, 2020
In 2020, European regulators are expected to start to be even more active in encouraging drugs innovations rather than hindering them through legal restrictions.
December 02, 2019
As the UK heads to the polls for an unusual December general election, industry issues manifestos on medicines while Europe rejoices some movement … finally.
November 02, 2019
Despite preparative work by the bio/pharma industry, any Brexit scenario will result in regulatory implications and increased costs.
October 22, 2019
The new location was established to ensure uninterrupted support for clients’ trials in both the United Kingdom and Europe if the UK leaves the European Union on Oct. 31, 2019, especially in the event of a no-deal Brexit.